摘要
在由蛋白质突变引起的许多构象性疾病中,细胞内的交通被破坏,导致减少或废除受影响蛋白的功能。Pharmacoperones(从“药物分子伴侣”)的化合物进入细胞并作为分子支架帮助错误折叠的突变蛋白的正确折叠,采用稳定的低能构象与适当的适当的胞内运输。Pharmacoperone的使用代表治疗错误折叠疾病最具前景的治疗方法。这类药物在体外和体内,在修复功能的突变体,错误折叠的蛋白质上已经成功了,包括酶、膜受体和离子通道。在这里,我们描述修复错误折叠的G蛋白偶联受体功能的策略,主要是促性腺激素释放激素受体,它已作为Pharmacoperone药品开发的一个有价值的模型,以更好地了解这一类特殊的化合物怎么由目标蛋白检测到正确的路由、表达和功能。
关键词: 构象病,促性腺激素释放激素受体,促性腺激素释放激素,促性腺功能低下,错误折叠的受体,药物分子伴侣,Pharmacoperones
图形摘要
Current Drug Targets
Title:Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules
Volume: 17 Issue: 13
Author(s): Alfredo Ulloa-Aguirre, P. Michael Conn
Affiliation:
关键词: 构象病,促性腺激素释放激素受体,促性腺激素释放激素,促性腺功能低下,错误折叠的受体,药物分子伴侣,Pharmacoperones
摘要: In many conformational diseases caused by protein mutations, the intracellular traffic of the misfolded protein is compromised, leading to reduced or abolished function of the affected protein. Pharmacoperones (from “pharmacological chaperones”) are compounds that enter cells and serve as a molecular scaffold to aid misfolded mutant proteins to fold properly and adopt a stable, low-energy native conformation compatible with proper intracellular trafficking. The use of pharmacoperones represents the most promising therapeutic approach to treat misfolding disorders. This class of drugs has succeeded, in vitro and in vivo, in rescuing function of mutant, misfolded proteins, including enzymes, membrane receptors and ion channels. Here we describe the strategies to rescue function of misfolded G protein-coupled receptors, mainly of the gonadotropin-releasing hormone receptor, which has served as a valuable model for the development of pharmacoperone drugs and to better understand how this class of particular compounds is sensed by the target protein to correct routing, expression and function.
Export Options
About this article
Cite this article as:
Alfredo Ulloa-Aguirre, P. Michael Conn , Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules, Current Drug Targets 2016; 17 (13) . https://dx.doi.org/10.2174/1389450117666160307143345
DOI https://dx.doi.org/10.2174/1389450117666160307143345 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PDE5 Inhibitors Offer Novel Mechanisms in Combination and Solo Cancer Therapy
Current Cancer Therapy Reviews Structure and Function of the Human Nuclear Xenobiotic Receptor PXR
Current Drug Metabolism XBP-1 and the UPRosome: Mastering Secretory Cell Function
Current Immunology Reviews (Discontinued) Potential Efficacy of Some African Plants in Benign Prostatic Hyperplasia and Prostate Cancer
Mini-Reviews in Medicinal Chemistry Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives
Current Pharmaceutical Design Instructions from the Vascular System - Directing Neural Stem Cell Fate in Health and Disease
Current Medicinal Chemistry Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets β-estradiol Induces Mitochondrial Apoptosis in Cervical Cancer through the Suppression of AKT/NF-κB Signaling Pathway
Recent Patents on Anti-Cancer Drug Discovery Functions of Ghrelin in Brain, Gut and Liver
CNS & Neurological Disorders - Drug Targets Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer
Reviews on Recent Clinical Trials Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
Current Cancer Drug Targets Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review
Current Alzheimer Research Sortase A Mediated Protein Modifications and Peptide Conjugations
Current Drug Discovery Technologies Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers
Cardiovascular & Hematological Agents in Medicinal Chemistry Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry